Radioimmunotherapy for delivery of cytotoxic radioisotopes: current status and challenges

References

• James ND, Hussain SA, Hall E, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med. 2012 Apr 19;366(16):1477–1488.
   PubMed Web of Science ®Google Scholar
• Cadet J, Ravanat JL, TavernaPorro M, et al. Oxidatively generated complex DNA damage: tandem and clustered lesions. Cancer Lett. 2012 Dec 31;327(1–2):5–15.
   PubMed Web of Science ®Google Scholar
• Rothkamm K, Kruger I, Thompson LH, et al. Pathways of DNA double-strand break repair during the mammalian cell cycle. Mol Cell Biol. 2003 Aug;23(16):5706–5715.
   PubMed Web of Science ®Google Scholar
• Mladenov E, Magin S, Soni A, et al. DNA double-strand break repair as determinant of cellular radiosensitivity to killing and target in radiation therapy. Front Oncol. 2013;3:113.
   PubMedGoogle Scholar
• Hunt CR, Ramnarain D, Horikoshi N, et al. Histone modifications and DNA double-strand break repair after exposure to ionizing radiations. Radiat Res. 2013 Apr;179(4):383–392.
   PubMed Web of Science ®Google Scholar
• Price BD, D’Andrea AD. Chromatin remodeling at DNA double-strand breaks. Cell. 2013 Mar 14;152(6):1344–1354.
   PubMed Web of Science ®Google Scholar
• Gulston M, De Lara C, Jenner T, et al. Processing of clustered DNA damage generates additional double-strand breaks in mammalian cells post-irradiation. Nucleic Acids Res. 2004;32(4):1602–1609.
   PubMed Web of Science ®Google Scholar
• Gulston M, Fulford J, Jenner T, et al. Clustered DNA damage induced by radiation in human fibroblasts (HF19), hamster (V79-4) cells and plasmid DNA is revealed as Fpg and Nth sensitive sites. Nucleic Acids Res. 2002 Aug 1;30(15):3464–3472.
   PubMed Web of Science ®Google Scholar
• Sutherland BM, Bennett PV, Sidorkina O, et al. Clustered DNA damages induced in isolated DNA and in human cells by low doses of ionizing radiation. Proc Natl Acad Sci USA. 2000 Jan 4;97(1):103–108.
   PubMed Web of Science ®Google Scholar
• Sutherland BM, Bennett PV, Sutherland JC, et al. Clustered DNA damages induced by X rays in human cells. Radiat Res. 2002 Jun;157(6):611–616.
   PubMed Web of Science ®Google Scholar
• Goodarzi AA, Jeggo PA. The repair and signaling responses to DNA double-strand breaks. Adv Genet. 2013;82:1–45.
   PubMed Web of Science ®Google Scholar
• Nikjoo H, O’Neill P, Wilson WE, et al. Computational approach for determining the spectrum of DNA damage induced by ionizing radiation. Radiat Res. 2001 Nov;156(5):577–583.
   PubMed Web of Science ®Google Scholar
• Jurcic JG. Radioimmunotherapy for hematopoietic cell transplantation. Immunotherapy. 2013 Apr;5(4):383–394.
   PubMed Web of Science ®Google Scholar
• Prise KM, O’Sullivan JM. Radiation-induced bystander signalling in cancer therapy. Nat Rev Cancer. 2009 May;9(5):351–360.
   PubMed Web of Science ®Google Scholar
• Larson SM, Carrasquillo JA, Cheung NKV, et al. Radioimmunotherapy of human tumours. Nat Rev Cancer. 2015 Jun;15(6):347–360.
   PubMed Web of Science ®Google Scholar
• Sharkey RM, Mottahennessy C, Pawlyk D, et al. Biodistribution and radiation-dose estimates for yttrium-labeled and iodine-labeled monoclonal-antibody igg and fragments in nude-mice bearing human colonic tumor xenografts. Cancer Res. 1990 Apr 15;50(8):2330–2336.
   PubMed Web of Science ®Google Scholar
• Seidl C, Zockler C, Beck R, et al. Lu-177-immunotherapy of experimental peritoneal carcinomatosis shows comparable effectiveness to Bi-213-immunotherapy, but causes toxicity not observed with Bi-213. Eur J Nucl Med Mol I. 2011 Feb;38(2):312–322.
   PubMed Web of Science ®Google Scholar
• Eisen HN, Keston AS. The immunologic reactivity of bovine serum albumin labeled with trace-amounts of radioactive iodine (I131). J Immunol. 1949 Sep;63(1):71–80.
   PubMed Web of Science ®Google Scholar
• Pressman D, Korngold L. The in vivo localization of anti-Wagner-osteogenic-sarcoma antibodies. Cancer. 1953 May;6(3):619–623.
   PubMed Web of Science ®Google Scholar
• Beierwaltes WH. Radioiodine-labelled compounds previously or currently used for tumour localization. Tumour localization with radioactive agents. International Atomic Energy Agency, Vienna (Austria); Panel proceedings series 1976; p. 47–53; ISBN 92-0-111276-9
   Google Scholar
• Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975 Aug 7;256(5517):495–497.
   PubMed Web of Science ®Google Scholar
• Tiernan JP, Perry SL, Verghese ET, et al. Carcinoembryonic antigen is the preferred biomarker for in vivo colorectal cancer targeting. Br J Cancer. 2013 Feb 19;108(3):662–667.
   PubMed Web of Science ®Google Scholar
• Ng D. Radioimmunotherapy: a brief overview. Biomed Imaging Interv J. 2006;2(3):e23–e.
   PubMedGoogle Scholar
• Rajendran JG, Gopal AK, Fisher DR, et al. Myeloablative 131I-tositumomab radioimmunotherapy in treating non-Hodgkin’s lymphoma: comparison of dosimetry based on whole-body retention and dose to critical organ receiving the highest dose. J Nucl Med. 2008 May;49(5):837–844.
   PubMed Web of Science ®Google Scholar
• Sharkey RM, Goldenberg DM. Cancer radioimmunotherapy. Immunotherapy. 2011 Mar;3(3):349–370.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 2002 May 15;20(10):2453–2463.
   PubMed Web of Science ®Google Scholar
• Davis TA, Kaminski MS, Leonard JP, et al. The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin Cancer Res. 2004 Dec 1;10(23):7792–7798.
   PubMed Web of Science ®Google Scholar
• Postema EJ, Oyen WJ, Boerman OC, et al. Administration guidelines for radioimmunotherapy of non-Hodgkin’s lymphoma with 90Y-labeled anti-CD20 monoclonal antibody. J Nucl Med. 2003 May;44(5):853.
   PubMed Web of Science ®Google Scholar
• Shimoni A, Zwas ST. Radioimmunotherapy and autologous stem-cell transplantation in the treatment of B-Cell non-hodgkin lymphoma. Semin Nucl Med. 2016 Mar;46(2):119–125.
   PubMed Web of Science ®Google Scholar
• Rizzieri D. Zevalin((R)) (ibritumomab tiuxetan): after more than a decade of treatment experience, what have we learned? Crit Rev Oncol Hematol. 2016 Sep;105:5–17.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin’s lymphoma. J Clin Oncol. 2002 Aug 01;20(15):3262–3269.
   PubMed Web of Science ®Google Scholar
• Janik JE, Morris JC, O’Mahony D, et al. 90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin’s lymphoma. Proc Natl Acad Sci U S A. 2015 Oct 20;112(42):13045–13050.
   PubMed Web of Science ®Google Scholar
• Lehnert S. Biomolecular action of ionizing radiation. Biomolecular action of ionizing radiation series: series in medical physics and biomedical engineering. Edited by. Lehnert S 2007. 1. Taylor & Francis. Oxfordshire, United Kingdom. ISBN: 978-0-7503-0824-3
   Google Scholar
• Goodhead DT. The initial physical damage produced by ionizing-radiations. Int J Radiat Biol. 1989 Nov;56(5):623–634.
   PubMed Web of Science ®Google Scholar
• Pouget JP, Navarro-Teulon I, Bardies M, et al. Clinical radioimmunotherapy-the role of radiobiology. Nat Rev Clin Oncol. 2011 Dec;8(12):720–734.
   PubMed Web of Science ®Google Scholar
• Delara CM, Jenner TJ, Townsend KMS, et al. The effect of dimethyl-sulfoxide on the induction of DNA double-strand breaks in V79-4 mammalian-cells by alpha-particles. Radiat Res. 1995 Oct;144(1):43–49.
   PubMed Web of Science ®Google Scholar
• Roots R, Okada S. Estimation of life times and diffusion distances of radicals involved in x-ray-induced DNA strand breaks or killing of mammalian-cells. Radiat Res. 1975;64(2):306–320.
   PubMed Web of Science ®Google Scholar
• Hirayama R, Ito A, Noguchi M, et al. OH radicals from the indirect actions of x-rays induce cell lethality and mediate the majority of the oxygen enhancement effect. Radiat Res. 2013 Nov;180(5):514–523.
   PubMed Web of Science ®Google Scholar
• Jain RK. Barriers to drug-delivery in solid tumors. Sci Am. 1994 Jul;271(1):58–65.
   PubMed Web of Science ®Google Scholar
• Press OW. Radioimmunotherapy for non-Hodgkin’s lymphomas: a historical perspective. Semin Oncol. 2003 Apr;30(2):10–21.
   PubMed Web of Science ®Google Scholar
• Press OW, Rasey J. Principles of radioimmunotherapy for hematologists and oncologists. Semin Oncol. 2000 Dec;27(6):62–73.
   PubMed Web of Science ®Google Scholar
• Barbet J, Bardies M, Bourgeois M, et al. Radiolabeled antibodies for cancer imaging and therapy. Methods Mol Biol. 2012;907:681–697.
   PubMedGoogle Scholar
• Navarro-Teulon I, Lozza C, Pelegrin A, et al. General overview of radioimmunotherapy of solid tumors. Immunotherapy. 2013 May;5(5):467–487.
   PubMed Web of Science ®Google Scholar
• Pouget JP, Lozza C, Deshayes E, et al. Introduction to radiobiology of targeted radionuclide therapy. Front Med (Lausanne). 2015;2:12.
   PubMedGoogle Scholar
• Pagel JM, Gooley TA, Rajendran J, et al. Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome. Blood. 2009 Dec 24;114(27):5444–5453.
   PubMed Web of Science ®Google Scholar
• Geissler F, Anderson SK, Press O. Intracellular catabolism of radiolabeled anti-cd3 antibodies by leukemic t-cells. Cell Immunol. 1991 Oct 1;137(1):96–110.
   PubMed Web of Science ®Google Scholar
• Vaidyanathan G, Zalutsky MR. Preparation of N-succinimidyl 3-[*I] iodobenzoate: an agent for the indirect radioiodination of proteins. Nat Protoc. 2006;1(2):707–713.
   PubMed Web of Science ®Google Scholar
• Milenic DE, Brady ED, Brechbiel MW. Antibody-targeted radiation cancer therapy. Nat Rev Drug Discov. 2004 Jun;3(6):488–499.
   PubMed Web of Science ®Google Scholar
• Koppe MJ, Postema EJ, Aarts F, et al. Antibody-guided radiation therapy of cancer. Cancer Met Rev. 2005 Dec;24(4):539–567.
   PubMed Web of Science ®Google Scholar
• Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I 131 Tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin’s lymphomas. J Clin Oncol. 2001 Oct 1;19(19):3918–3928.
   PubMed Web of Science ®Google Scholar
• Seidl C. Radioimmunotherapy with alpha-particle-emitting radionuclides. Immunotherapy. 2014;6(4):431–458.
   PubMed Web of Science ®Google Scholar
• Seidl C, Essler M. Radioimmunotherapy for peritoneal cancers. Immunotherapy. 2013 Apr;5(4):395–405.
   PubMed Web of Science ®Google Scholar
• Wulbrand C, Seidl C, Gaertner FC, et al. Alpha-particle emitting 213Bi-anti-EGFR immunoconjugates eradicate tumor cells independent of oxygenation. PLoS One. 2013;8(5):e64730.
   PubMed Web of Science ®Google Scholar
• Kim YS, Brechbiel MW. An overview of targeted alpha therapy. Tumor Biol. 2012 Jun;33(3):573–590.
   PubMed Web of Science ®Google Scholar
• Jackson MR, Falzone N, Vallis KA. Advances in anticancer radiopharmaceuticals. Clin Oncol. 2013 Oct;25(10):604–609.
   Web of Science ®Google Scholar
• Kassis AI. Molecular and cellular radiobiological effects of auger emitting radionuclides. Radiat Prot Dosim. 2011 Feb;143(2–4):241–247.
   PubMed Web of Science ®Google Scholar
• Reilly RM. Monoclonal antibody and peptide-targeted radiotherapy of cancer. Hoboken, NJ, USA:John Wiley & Sons; 2010.
   Google Scholar
• Li HK, Morokoshi Y, Daino K, et al. Transcriptomic signatures of auger electron radioimmunotherapy using nuclear targeting (111)In-trastuzumab for potential combination therapies. Cancer Biother Radiopharm. 2015 Oct;30(8):349–358.
   PubMed Web of Science ®Google Scholar
• Morris MJ, Divgi CR, Pandit-Taskar N, et al. Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer. Clin Cancer Res. 2005 Oct 15;11(20):7454–7461.
   PubMed Web of Science ®Google Scholar
• Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012 Apr;12(4):278–287.
   PubMed Web of Science ®Google Scholar
• DeNardo SJ, OGrady LF, Richman CM, et al. Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody. Anticancer Res. 1997 May-Jun;17(3b):1745–1751.
   PubMed Web of Science ®Google Scholar
• Navarro-Teulon I, Lozza C, Pèlegrin A, et al. General overview of radioimmunotherapy of solid tumors. Immunotherapy. 2013;5(5):467–487.
   PubMed Web of Science ®Google Scholar
• Reardon DA, Akabani G, Coleman RE, et al. Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. J Clin Oncol. 2006 Jan 1;24(1):115–122.
   PubMed Web of Science ®Google Scholar
• Akabani G, Reardon DA, Coleman RE, et al. Dosimetry and radiographic analysis of 131I-labeled anti− tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a Phase II study. J Nucl Med. 2005;46(6):1042–1051.
   PubMed Web of Science ®Google Scholar
• Divgi CR, O’Donoghue JA, Welt S, et al. Phase I clinical trial with fractionated radioimmunotherapy using I-13-labeled chimeric G250 in metastatic renal cancer. J Nucl Med. 2004 Aug;45(8):1412–1421.
   PubMed Web of Science ®Google Scholar
• Vallabhajosula S, Nikolopoulou AS, Jhanwar Y, et al. Radioimmunotherapy of metastatic prostate cancer with; 177Lu-DOTAhuJ591 anti prostate specific membrane antigen specific monoclonal antibody. Curr Radiopharm. 2016;9(1):44–53.
   PubMed Web of Science ®Google Scholar
• Kang CS, Song HA, Milenic DE, et al. Preclinical evaluation of NETA-based bifunctional ligand for radioimmunotherapy applications using 212Bi and 213Bi: radiolabeling, serum stability, and biodistribution and tumor uptake studies. Nucl Med Biol. 2013 Jul;40(5):600–605.
   PubMed Web of Science ®Google Scholar
• Timmermand OV, Larsson E, Ulmert D, et al. Radioimmunotherapy of prostate cancer targeting human kallikrein-related peptidase 2. Eur J Nucl Med Mol Imaging Res. 2016;6(1):1.
   Google Scholar
• Derrien A, Gouard S, Maurel C, et al. Therapeutic efficacy of alpha-RIT using a 213Bi-anti-hCD138 antibody in a mouse model of ovarian peritoneal carcinomatosis. Front Med. 2015;2:88.
   Web of Science ®Google Scholar
• Song IH, Lee TS, Park JH, et al. Immuno-PET imaging and radioimmunotherapy of 64Cu/177Lu labeled anti-EGFR antibody in esophageal squamous cell carcinoma. J Nucl Med. 2015;56(supplement 3):1216.
   Web of Science ®Google Scholar
• Van Rij CM, Frielink C, Goldenberg DM, et al. Pretargeted radioimmunotherapy of prostate cancer with an anti-TROP-2× Anti-HSG bispecific antibody and a 177Lu-Labeled Peptide. Cancer Biother Radiopharm. 2014;29(8):323–329.
   PubMed Web of Science ®Google Scholar
• Van Rij C, Franssen G, Sharkey R, et al. Pretargeted immunoPET imaging and radioimmunotherapy (RIT) of prostate cancer with an anti-EGP1 x anti-HSG bispecific antibody (bsMAb). J Nucl Med. 2010;51(supplement 2):501.
   PubMedGoogle Scholar
• Cheal SM, Xu H, Guo HF, et al. Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity (86)Y- or (177)Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates. Eur J Nucl Med Mol Imaging Res. 2016 May;43(5):925–937.
   PubMed Web of Science ®Google Scholar
• Cederkrantz E, Andersson H, Bernhardt P, et al. Absorbed doses and risk estimates of (211)At-MX35 F(ab’)2 in intraperitoneal therapy of ovarian cancer patients. Int J Radiat Oncol Biol Phys. 2015 Nov 1;93(3):569–576.
   PubMed Web of Science ®Google Scholar
• Altai M, Wallberg H, Honarvar H, et al. Re-188-Z(HER2:V2),a promising affibody-based targeting agent against HER2-expressing tumors: preclinical assessment. J Nucl Med. 2014 Nov;55(11):1842–1848.
   PubMed Web of Science ®Google Scholar
• Orlova A, Jonsson A, Rosik D, et al. Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein. J Nucl Med. 2013 Jun 1;54(6):961–968.
   PubMed Web of Science ®Google Scholar
• Yong KJ, Milenic DE, Baidoo KE, et al. (212)Pb-radioimmunotherapy induces G(2) cell-cycle arrest and delays DNA damage repair in tumor xenografts in a model for disseminated intraperitoneal disease. Mol Cancer Ther. 2012 Mar;11(3):639–648.
   PubMed Web of Science ®Google Scholar
• Rousseau C, Ruellan AL, Bernardeau K, et al. Syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-PET and radioimmunotherapy. A preclinical study on MDA-MB-468 xenograft tumors. Eur J Nucl Med Mol Imaging Res. 2011;1:20.
   Google Scholar
• Abbas N, Heyerdahl H, Bruland ØS, et al. Experimental α-particle radioimmunotherapy of breast cancer using 227Th-labeled p-benzyl-DOTA-trastuzumab. Eur J Nucl Med Mol Imaging Res. 2011;1(1):1–12.
   Google Scholar
• Zacchetti A, Martin F, Luison E, et al. Antitumor effects of a human dimeric antibody fragment 131I-AFRA-DFM5.3 in a mouse model for ovarian cancer. J Nucl Med. 2011 Dec;52(12):1938–1946.
   PubMed Web of Science ®Google Scholar
• Vera DR, Eigner S, Henke KE, et al. Preparation and preclinical evaluation of 177Lu-nimotuzumab targeting epidermal growth factor receptor overexpressing tumors. Nucl Med Biol. 2012 Jan;39(1):3–13.
   PubMed Web of Science ®Google Scholar
• Salouti M, Babaei MH, Rajabi H, et al. Preparation and biological evaluation of (177)Lu conjugated PR81 for radioimmunotherapy of breast cancer. Nucl Med Biol. 2011 Aug;38(6):849–855.
   PubMed Web of Science ®Google Scholar
• Rasaneh S, Rajabi H, Babaei MH, et al. 177 Lu labeling of Herceptin and preclinical validation as a new radiopharmaceutical for radioimmunotherapy of breast cancer. Nucl Med Biol. 2010;37(8):949–955.
   PubMed Web of Science ®Google Scholar
• Josefsson A, Nedrow JR, Park S, et al. Imaging, biodistribution, and dosimetry of radionuclide-labeled PD-L1 antibody in an immunocompetent mouse model of breast cancer. Cancer Res. 2016 Jan 15;76(2):472–479.
   PubMed Web of Science ®Google Scholar
• Razumienko EJ, Chen JC, Cai ZL, et al. Dual-receptor-targeted radioimmunotherapy of human breast cancer xenografts in athymic mice coexpressing HER2 and EGFR Using Lu-177- or In-111-labeled bispecific radioimmunoconjugates. J Nucl Med. 2016 Mar;57(3):444–452.
   PubMed Web of Science ®Google Scholar
• Fazel J, Rotzer S, Seidl C, et al. Fractionated intravesical radioimmunotherapy with Bi-213-anti-EGFR-MAb is effective without toxic side-effects in a nude mouse model of advanced human bladder carcinoma. Cancer Biol Ther. 2015 Oct;16(10):1526–1534.
   PubMed Web of Science ®Google Scholar
• Lindenblatt D, Fischer E, Cohrs S, et al. Paclitaxel improved anti-L1CAM lutetium-177 radioimmunotherapy in an ovarian cancer xenograft model. Eur J Nucl Med Mol Imaging Res. 2014 Oct;3:4.
   Google Scholar
• Fujiwara K, Koyama K, Suga K, et al. 90Y-labeled anti-ROBO1 monoclonal antibody exhibits antitumor activity against small cell lung cancer xenografts. PLoS One. 2015;10(5):e0125468.
   PubMed Web of Science ®Google Scholar
• Sugyo A, Tsuji AB, Sudo H, et al. Evaluation of efficacy of radioimmunotherapy with 90Y-labeled fully human anti-transferrin receptor monoclonal antibody in pancreatic cancer mouse models. PLoS One. 2015;10(4):e0123761.
   PubMed Web of Science ®Google Scholar
• Elgstrom E, Eriksson SE, Ohlsson TG, et al. Role of CD8 positive cells in radioimmunotherapy utilizing 177Lu-mAb in a syngeneic rat colon carcinoma model. Eur J Nucl Med Mol Imaging. 2014 Oct;41:S533–S.
   Web of Science ®Google Scholar
• Kratochwil C, Bruchertseifer F, Giesel FL, et al. 225Ac-PSMA-617 for PSMA-targeted alpha-radiation therapy of metastatic castration-resistant prostate cancer. J Nucl Med. 2016 Dec;57(12):1941–1944.
   PubMed Web of Science ®Google Scholar
• Niu G, Sun XL, Cao QZ, et al. Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma. Clin Cancer Res. 2010 Apr 1;16(7):2095–2105.
   PubMed Web of Science ®Google Scholar
• Palm S, Back T, Claesson I, et al. Therapeutic efficacy of astatine-211-labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice. Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):572–579.
   PubMed Web of Science ®Google Scholar
• Lindegren S, Andrade LN, Back T, et al. Binding affinity, specificity and comparative biodistribution of the parental murine monoclonal antibody MX35 (Anti-NaPi2b) and its humanized version rebmab200. PLoS One. 2015;10(5):e0126298.
   PubMed Web of Science ®Google Scholar
• Frost SH, Back T, Chouin N, et al. Comparison of 211At-PRIT and 211At-RIT of ovarian microtumors in a nude mouse model. Cancer Biother Radiopharm. 2013 Mar;28(2):108–114.
   PubMed Web of Science ®Google Scholar
• Cederkrantz E, Angenete E, Back T, et al. Evaluation of effects on the peritoneum after intraperitoneal alpha-radioimmunotherapy with (211)At. Cancer Biother Radiopharm. 2012 Aug;27(6):353–364.
   PubMed Web of Science ®Google Scholar
• Gustafsson AM, Back T, Elgqvist J, et al. Comparison of therapeutic efficacy and biodistribution of 213Bi- and 211At-labeled monoclonal antibody MX35 in an ovarian cancer model. Nucl Med Biol. 2012 Jan;39(1):15–22.
   PubMed Web of Science ®Google Scholar
• Andersson H, Cederkrantz E, Back T, et al. Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab’)2–a phase I study. J Nucl Med. 2009 Jul;50(7):1153–1160.
   PubMed Web of Science ®Google Scholar
• Chevallier P, Eugene T, Robillard N, et al. (90)Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study. Lancet Haematol. 2015 Mar;2(3):e108–17.
   PubMed Web of Science ®Google Scholar
• Cheal SM, Xu H, Guo H-F, et al. Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity 86Y-or 177Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates. Eur J Nucl Med Mol Imaging. 2016 May;43(5):925–937.
   Google Scholar
• Olafsen T, Wu AM. Antibody vectors for imaging. Semin Nucl Med. 2010 May;40(3):167–181.
   PubMed Web of Science ®Google Scholar
• Behr TM, Memtsoudis S, Sharkey RM, et al. Experimental studies on the role of antibody fragments in cancer radio-immunotherapy: influence of radiation dose and dose rate on toxicity and anti-tumor efficacy. Int J Cancer. 1998 Aug 31;77(5):787–795.
   PubMed Web of Science ®Google Scholar
• Behr TM, Sharkey RM, Sgouros G, et al. Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates - Improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetry. Cancer. 1997 Dec 15;80(12):2591–2610.
   PubMed Web of Science ®Google Scholar
• Vegt E, De Jong M, Wetzels JFM, et al. Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention. J Nucl Med. 2010 Jul 1;51(7):1049–1058.
   PubMed Web of Science ®Google Scholar
• Tolmachev V, Orlova A, Pehrson R, et al. Radionuclide therapy of HER2-positive microxenografts using a Lu-177-labeled HER2-specific affibody molecule. Cancer Res. 2007 Mar 15;67(6):2773–2782.
   PubMed Web of Science ®Google Scholar
• Tolmachev V, Wallberg H, Andersson K, et al. The influence of Bz-DOTA and CHX-A”-DTPA on the biodistribution of ABD-fused anti-HER2 affibody molecules: implications for (114m)In-mediated targeting therapy. Eur J Nucl Med Mol Imaging. 2009 Sep;36(9):1460–1468.
   PubMed Web of Science ®Google Scholar
• Murray PJ, Cornelissen B, Vallis KA, et al. DNA double-strand break repair: a theoretical framework and its application. J R Soc Interface. 2016 Jan;13(114):20150679.
   PubMed Web of Science ®Google Scholar
• Boswell CA, Brechbiel MW. Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view. Nucl Med Biol. 2007 Oct;34(7):757–778.
   PubMed Web of Science ®Google Scholar
• Schaefer NG, Huang P, Buchanan JW, et al. Radioimmunotherapy in non-Hodgkin lymphoma: opinions of nuclear medicine physicians and radiation oncologists. J Nucl Med. 2011 May;52(5):830–838.
   PubMed Web of Science ®Google Scholar
• Verheijen RH, Massuger LF, Benigno BB, et al. Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. J Clin Oncol. 2006 Feb 1;24(4):571–578.
   PubMed Web of Science ®Google Scholar
• Joiner MC, Van Der Kogel A. Basic clinical radiobiology. Boca Raton, FL, USA:CRC Press; 2016.
   Google Scholar
• Gunderson LL, Tepper JE. Clinical radiation oncology. Philadelphia, PA, USA:Elsevier Health Sciences; 2015.
   Google Scholar
• Tempero M, Leichner P, Baranowska-Kortylewicz J, et al. High-dose therapy with (90)yttrium-labeled monoclonal antibody CC49: a phase I trial. Clin Cancer Res. 2000 Aug;6(8):3095–3102.
   PubMed Web of Science ®Google Scholar
• Schwartz J, Humm JL, Divgi CR, et al. Bone marrow dosimetry using I-124-PET. J Nucl Med. 2012 Apr;53(4):615–621.
   PubMed Web of Science ®Google Scholar
• Rösch F, Baum RP. Generator-based PET radiopharmaceuticals for molecular imaging of tumours: on the way to THERANOSTICS. Dalton Trans. 2011;40(23):6104–6111.
   PubMed Web of Science ®Google Scholar
• Kolsky K, Joshi V, Mausner L, et al. Radiochemical purification of no-carrier-added scandium-47 for radioimmunotherapy. Appl Radiat Isot. 1998;49(12):1541–1549.
   PubMed Web of Science ®Google Scholar
• Müller C, Bunka M, Haller S, et al. Promising prospects for 44Sc-/47Sc-based theragnostics: application of 47Sc for radionuclide tumor therapy in mice. J Nucl Med. 2014;55(10):1658–1664.
   PubMed Web of Science ®Google Scholar
• Połosak M, Piotrowska A, Krajewski S, et al. Stability of 47Sc-complexes with acyclic polyamino-polycarboxylate ligands. J Radioanal Nucl Chem. 2013;295(3):1867–1872.
   PubMed Web of Science ®Google Scholar
• Su FM, Beaumier P, Axworthy D, et al. Pretargeted radioimmunotherapy in tumored mice using an in vivo Pb-212/Bi-212 generator. Nucl Med Biol. 2005 Oct;32(7):741–747.
   PubMed Web of Science ®Google Scholar
• Ma D, McDevitt MR, Finn RD, et al. Breakthrough of 225Ac and its radionuclide daughters from an 225Ac/213Bi generator: development of new methods, quantitative characterization, and implications for clinical use. Appl Radiat Isot. 2001 Nov;55(5):667–678.
   PubMed Web of Science ®Google Scholar
• Boll RA, Malkemus D, Mirzadeh S. Production of actinium-225 for alpha particle mediated radioimmunotherapy. Appl Radiat Isot. 2005 May;62(5):667–679.
   PubMed Web of Science ®Google Scholar
• Yong K, Brechbiel MW. Towards translation of 212Pb as a clinical therapeutic; getting the lead in! Dalton Trans. 2011 Jun 21;40(23):6068–6076.
   PubMed Web of Science ®Google Scholar
• Boerman OC, Van Schaijk FG, Oyen WJG, et al. Pretargeted radioimmunotherapy of cancer: progress step by step. J Nucl Med. 2003 Mar;44(3):400–411.
   PubMed Web of Science ®Google Scholar
• Schoffelen R, Boerman OC, Goldenberg DM, et al. Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: first clinical results. Br J Cancer. 2013 Aug 20;109(4):934–942.
   PubMed Web of Science ®Google Scholar
• Salaun PY, Campion L, Bournaud C, et al. Phase II trial of anticarcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: biomarker response and survival improvement. J Nucl Med. 2012 Aug;53(8):1185–1192.
   PubMed Web of Science ®Google Scholar
• Kraeber-Bodere F, Salaun PY, Ansquer C, et al. Pretargeted radioimmunotherapy (pRAIT) in medullary thyroid cancer (MTC). Tumour Biol. 2012 Jun;33(3):601–606.
   PubMed Web of Science ®Google Scholar
• Bodet-Milin C, Faivre-Chauvet A, Carlier T, et al. Immuno-PET using anticarcinoembryonic antigen bispecific antibody and 68Ga-labeled peptide in metastatic medullary thyroid carcinoma: clinical optimization of the pretargeting parameters in a first-in-human trial. J Nucl Med. 2016 Oct;57(10):1505–1511.
   PubMed Web of Science ®Google Scholar
• Bodet-Milin C, Ferrer L, Rauscher A, et al. Pharmacokinetics and dosimetry studies for optimization of pretargeted radioimmunotherapy in CEA-expressing advanced lung cancer patients. Front Med (Lausanne). 2015;2:84.
   PubMed Web of Science ®Google Scholar
• Houghton JL, Zeglis BM, Abdel-Atti D, et al. Pretargeted immuno-PET of pancreatic cancer: overcoming circulating antigen and internalized antibody to reduce radiation doses. J Nucl Med. 2016 Mar;57(3):453–459.
   PubMed Web of Science ®Google Scholar
• Zeglis BM, Brand C, Abdel-Atti D, et al. Optimization of a pretargeted strategy for the pet imaging of colorectal carcinoma via the modulation of radioligand pharmacokinetics. Mol Pharm. 2015 Oct 5;12(10):3575–3587.
   PubMed Web of Science ®Google Scholar
• Ashrafi SA, Hosseinimehr SJ, Varmira K, et al. Radioimmunotherapy with 131I-bevacizumab as a specific molecule for cells with overexpression of the vascular endothelial growth factor. Cancer Biother Radiopharm. 2012;27(7):420–425.
   PubMed Web of Science ®Google Scholar
• Desar IM, Stillebroer AB, Oosterwijk E, et al. 111In-bevacizumab imaging of renal cell cancer and evaluation of neoadjuvant treatment with the vascular endothelial growth factor receptor inhibitor sorafenib. J Nucl Med. 2010 Nov;51(11):1707–1715.
   PubMed Web of Science ®Google Scholar
• Muselaers CH, Stillebroer AB, Desar IM, et al. Tyrosine kinase inhibitor sorafenib decreases 111In-girentuximab uptake in patients with clear cell renal cell carcinoma. J Nucl Med. 2014 Feb;55(2):242–247.
   PubMed Web of Science ®Google Scholar
• Miyamoto R, Oda T, Hashimoto S, et al. Cetuximab delivery and antitumor effects are enhanced by mild hyperthermia in a xenograft mouse model of pancreatic cancer. Cancer Sci. 2016 Apr;107(4):514–520.
   PubMed Web of Science ®Google Scholar
• Aquino A, Formica V, Prete SP, et al. Drug-induced increase of carcinoembryonic antigen expression in cancer cells. Pharmacol Res. 2004 May;49(5):383–396.
   PubMed Web of Science ®Google Scholar
• Eftekhar E, Naghibalhossaini F. Carcinoembryonic antigen expression level as a predictive factor for response to 5-fluorouracil in colorectal cancer. Mol Biol Rep. 2014 Jan;41(1):459–466.
   PubMed Web of Science ®Google Scholar
• Lee HC, Ling QD, Yu WC, et al. Drug-resistant colon cancer cells produce high carcinoembryonic antigen and might not be cancer-initiating cells. Drug Des Dev Ther. 2013;7:491–502.
   PubMed Web of Science ®Google Scholar
• Brouwers AH, Frielink C, Oosterwijk E, et al. Interferons can upregulate the expression of the tumor associated antigen G250-MN/CA IX, a potential target for (radio)immunotherapy of renal cell carcinoma. Cancer Biother Radiopharm. 2003 Aug;18(4):539–547.
   PubMed Web of Science ®Google Scholar